News

Immutep Moves Forward with Breakthrough Trial of IMP761

Immutep Moves Forward with Breakthrough Trial of IMP761

Immutep Making Significant Progress with IMP761 Trial

Media Release

First safety data anticipated before year-end with PK/PD assessments to follow.

Immutep Limited (ASX: IMM; NASDAQ: IMMP), a cutting-edge biotechnology firm, is excited to announce that its Phase I clinical trial of IMP761 has reached a pivotal point. The initial phase of the study, designed to evaluate this innovative LAG-3 immunotherapy, is now fully recruited, and participants have begun receiving the medication without reported safety issues.

From Single Doses to Escalating Findings

The trial, taking place at the Centre for Human Drug Research (CHDR) in the Netherlands, has passed the first stage and is now entering the dose escalation segment. This stage involves administering escalating doses of IMP761 starting at 0.03 mg/kg and potentially reaching up to 0.90 mg/kg for 30 healthy volunteers. The primary focus here will be on both safety and pharmacokinetic (PK) as well as pharmacodynamic (PD) analyses.

Anticipating Enthusiastic Results

As the trial progresses, CHDR will utilize a special model known as the keyhole limpet haemocyanin (KLH) challenge in order to assess the pharmacodynamic activity of IMP761 at this early but critical phase of development. Immutep is optimistic about sharing initial safety data by the end of the year, with further detailed insights regarding PK/PD relationships expected in the first half of the next calendar year.

The Promise of IMP761

IMP761 is a unique first-in-class immunosuppressive LAG-3 agonist antibody, which targets the fundamental causes of various autoimmune diseases. By specifically suppressing memory T cells that accumulate in inflamed tissues, this therapy hopes to restore balance in the immune system.

Exciting Preclinical Findings

Recent preclinical studies highlight the potential of IMP761 to inhibit crucial responses in T cell proliferation and activation, showcasing its promise in managing conditions like oligoarticular juvenile idiopathic arthritis (o-JIA). Results published in notable journals have demonstrated that IMP761 significantly reduces inflammatory responses in just 48 hours for patients suffering from o-JIA, suggesting children with altered LAG-3 metabolism may greatly benefit from this therapy.

About Immutep and Its Vision

Immutep is at the forefront of biotechnology, specializing in the development of innovative therapies centered around LAG-3 mechanisms, aiming to treat both cancer and autoimmune diseases. With a diverse portfolio, the company is committed to advancing treatment options while also maximizing value for its shareholders.

Dedicated Support for Investors and Media

For further inquiries regarding this trial or for media engagement, investors and media representatives are urged to reach out to the respective contacts provided by Immutep. This includes representatives in both Australia and the U.S., who are dedicated to facilitating clear and informative communication regarding ongoing developments.

Frequently Asked Questions

What is the focus of Immutep's IMP761 study?

The study focuses on evaluating IMP761's safety and its pharmacokinetic and pharmacodynamic properties in healthy volunteers.

How does IMP761 work?

IMP761 is designed to suppress autoimmune memory T cells to help restore balance to the immune system, targeting the underlying causes of autoimmune diseases.

What results is Immutep expecting in the trial?

Immutep anticipates the first safety data to be available before the year ends and further PK/PD assessments in the first half of the following year.

Who is leading the clinical trial?

The trial is being conducted by the Centre for Human Drug Research (CHDR) in the Netherlands.

How can I find more information about Immutep?

For more details about Immutep and its ongoing trials, interested parties can visit the official website of Immutep.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 56

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading
Four Data Quality Champions Put Trust on the Board

Updated Category News Views 65

A single rotten customer record can gum up an entire operation faster than most executives care to admit. Bad data does not merely make a dashboard look silly; it can foul forecasts, duplicate work, misdirect automation, and leave an AI project confidently spouting nonsense. That is why Infotech's 2026 Data Quality Emotional Footprint report deserves a look, even if...

Continue Reading
APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 51

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 55

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 47

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 90

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading
Oman’s Dhofar II Wind Deal Clears Financing Hurdle

Updated Category News Views 111

Dhofar’s next wind farm has crossed the line that matters: financial close. That is less glamorous than turbines spinning against an Omani skyline, but it is the point where a project stops being an attractive deck and becomes a real contractual obligation. Sembcorp Utilities, alongside OQ Alternative Energy through Naseem Dhofar SAOC, has brought the 125-megawatt...

Continue Reading
Milwaukee County Contract Tests Wisconsin Labor Shift

Updated Category News Views 6

A unanimous first contract in a Milwaukee County department is not the sort of headline that rattles a trading screen, but it can tell you plenty about where the ground is moving. Public safety workers in the county Facilities Department have ratified their first agreement with Teamsters Local 344, according to the union. The vote matters less for any disclosed economic...

Continue Reading
Sleep Number’s Couples Pitch Has Some Fine Print Too

Updated Category News Views 75

A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...

Continue Reading
News Articles" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles